Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor.
FDA Withdraws Approval of FGFR Inhibitor for Bile Duct Cancer
The FDA has withdrawn the approval of infigratinib (Truseltiq) as a second-line treatment for metastatic cholangiocarcinoma at the request of the drugmaker, the agency announced